Sunday, September 20, 2026

health-technology

5 articles

Canadian AI Heart Diagnostics Firm Risks Capital Wipeout as Cboe Listing Hangs in Balance

Canadian AI Heart Diagnostics Firm Risks Capital Wipeout as Cboe Listing Hangs in Balance

GuideAI Health Corp.'s conditional Cboe Canada listing could force a full return of investor proceeds if exchange requirements go unmet. The company is building AI diagnostics for cardiovascular disease — the world's leading killer — at a moment when clinical AI firms globally face high barriers to public capital. A failed listing would unwind its entire post-combination structure.

LM Salvado
U.S. Radiology Giant Posts 36% EBITDA Jump, Offering AI Benchmark for Global Health Systems

U.S. Radiology Giant Posts 36% EBITDA Jump, Offering AI Benchmark for Global Health Systems

RadNet's adjusted EBITDA rose 36.3% year-over-year in Q1 2026, well ahead of its 22.1% revenue growth, driven by AI scheduling and diagnostic tools across its U.S. network. Advanced imaging volumes surged, with PET/CT up 35.2% and MRI same-center volume up 10.1%. The margin expansion offers a concrete financial reference point for hospital systems worldwide evaluating AI investment in radiology.

LM Salvado
Intuitive Surgical's da Vinci 5 Clears Europe and Japan, Opening $2.3B Market as Q4 Beats Forecast

Intuitive Surgical's da Vinci 5 Clears Europe and Japan, Opening $2.3B Market as Q4 Beats Forecast

Intuitive Surgical secured regulatory approvals for its da Vinci 5 robotic system in Europe and Japan, unlocking markets worth $2.3 billion in annual surgical robotics spending. The company beat Q4 earnings forecasts while installing 415 systems globally, a 22% increase year-over-year. Force feedback and AI-powered features distinguish the new platform as competition intensifies across international markets.

ViaNews Editorial Team
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Boom Hits a Fork: Slowdown Calls Clash with Capex Confidence as Markets Get Nervous
Dario Amodei's repeated calls for a global slowdown in frontier AI development, echoed by Microsoft's new humanist AI code of conduct and FTC antitrust caution, are being publicly rejected by Nvidia and Meta leadership even as hyperscaler spending draws fresh skeptical scrutiny (Wachter's analysis, Burry-style overbuilding worries) and weak guidance from Adobe and a post-slowdown-comment selloff in GE Vernova signal investor jitters. Meanwhile wealth and security effects of the AI race keep compounding — Zhang Yiming's fortune surging on AI-driven ByteDance value, a Chinese hacking firm weaponizing AI against stolen government secrets, and low-quality AI-generated products (an AI sitcom, a spam-flooding agent platform) fueling backlash even as adoption races ahead.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Berkshire Hathaway
Both facts report Berkshire Hathaway's cash position on 2026-01-01 with identical observation timestamps, but claim vastly different values: 380 billion USD vs 400 USD. These cannot both be true for the same entity at the same point in time. The magnitude of the discrepancy (a factor of ~10^9) rules out rounding, unit conversion, or methodological differences.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,982
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,982 facts checked against source5,299 source documents archived
Query this data → isubstrate.com